SHL to speak at the 18th Annual Drug Delivery Partnership in Florida, USA
pharmafile | January 15, 2014 | News story | Manufacturing and Production | auto injector, autoinjectors, ddp 2014, pen injector, shl partnerships
According to a recent industry report, more than 75% of biologics are administered either subcutaneously or intramuscularly via a form of drug delivery technology, and with the continuous surge of biologics in biopharma company pipelines worldwide, the drug delivery technologies market is anticipated to grow to over $224 billion USD in the next few years. Within this, self-injection devices such as auto injectors and pen injectors have quickly become one of the most preferred technologies due to benefits such as ease-of-use, safety (from needle-stick injuries), efficacy, patient compliance, and more. As one of the world’s leaders in the design, development and manufacturing of auto injectors and pen injectors, SHL continues to connect with various biopharmaceutical companies and potential partners at different key events to in order to share information about new devices and technologies, as well as learn more about market trends and the related needs of end users.
One of the first events SHL will be attending in 2014 will be the 18th Annual Drug Delivery Partnership in Boca Raton, Florida, a location very close to SHL’s newest final assembly facility. DDP will take place from January 27-29th. Aside from key SHL staff attending, SHL’s Global Marketing Director Steven Kaufman will be one of the guest speakers speaking on January 28th at 2pm and he will also join a panel discussion on drug delivery shortly after. Commenting on the event, Kaufman stated, “As a company that has been designing, developing and manufacturing auto injectors and pen injectors for many years, we have witnessed the incredible growth and the changing demands of this drug delivery device market, requiring us to adapt and grow along with it. While we have introduced several breakthrough devices such as the DAI™ (Disposable Auto Injector) and Molly™ Auto Injector that are now often used as industry benchmarks, we recognize that it is paramount we continue to innovate and connect with industry leaders to partner with, and I believe that this event will provide us with an ideal stage to do so. We are extremely excited as this will be our first time attending this prestigious event and we look forward to the various sessions held by some of the industry’s most respected experts.”
A special podcast held by Drug Delivery Partnerships interviewing SHL’s Mr. Kaufman will be available online soon.
About SHL
SHL is the world’s largest privately-owned designer, developer and manufacturer of advanced drug delivery devices such as auto injectors and pen injectors. We have over 2,500 staff globally, with our primary design centers located in the USA and Sweden and manufacturing centers located in Asia. SHL supplies auto injectors, pen injectors and inhaler systems to global pharmaceutical and biotech companies. Significant investment in R&D has enhanced our broad pipeline of “next generation” drug delivery systems. These innovative devices include a range of disposable and reusable injectors with fixed or variable dosing, enhanced precision and the ability to accommodate high viscosities.
Our organization consists of several distinct group companies:
SHL Medical
Designs, develops and manufactures advanced drug delivery devices for leading pharmaceutical and biotech companies
SHL Healthcare
Develops and manufactures equipment solutions for home, hospital and long term care use
SHL Technologies
Provides contract manufacturing and engineering services for the production of complex medtech and industrial products
SHL Pharma
Provides final assembly, labeling and packaging services of drug delivery devices to the pharmaceutical and biotechnology industries
For additional information visit www.shl-group.com or contact us at info@shl-group.com
SHL Media Contact
Steven R. Kaufman
Marketing Director
+886 32170303
pr@shl-group.com
Related Content
Novartis secures US rights to Adamis’ epinephrine auto injector
Novartis has penned an agreement with Adamis Pharmaceuticals to commercialise and distribute the latter’s epinephrine …
FDA unveils guidelines to help generic medical device versions reach the market
The scandal surrounding Mylan’s price-hiking of its flagship EpiPen epinephrine auto-injector was the news of …
SHL brings innovation to Pharmapack Europe 2017
As a forward-looking company with extensive knowledge and experience, SHL delivers solutions for today on …
